Alterity's ATH434 Phase 2 Trial Shows Clinically Meaningful Efficacy In MSA Patients

(RTTNews) - Alterity Therapeutics Limited (ATHE), Thursday announced the data from ATH434 Phase 2 trial in patients with Multiple System Atrophy or MSA.

The findings showed clinically meaningful efficacy across multiple measures. ATH434 demonstrated a 48% decrease in clinical progression at the 50 mg dose, and a 30% decrease in clinical progression at the 75 mg dose at 52 weeks.

Additionally, improvements were observed in the Clinical Global Impression of Severity Scale at 50 mg, and favorable trends in the Orthostatic Hypotension Symptom Assessment.

Further, the study found that sensor-derived metrics, specifically those measuring walking and postural transitions, may increase the understanding of impairments associated with MSA.

The findings also confirmed target engagement with reduced iron signal in MSA affected brain regions.

In the pre-market hours, Alterity's stock is climbing 7.01 percent, to $2.9 on the Nasdaq.